MX366837B - Quinolinas carboxamidas para usarse en el tratamiento de mielomas multiples. - Google Patents
Quinolinas carboxamidas para usarse en el tratamiento de mielomas multiples.Info
- Publication number
- MX366837B MX366837B MX2017003294A MX2017003294A MX366837B MX 366837 B MX366837 B MX 366837B MX 2017003294 A MX2017003294 A MX 2017003294A MX 2017003294 A MX2017003294 A MX 2017003294A MX 366837 B MX366837 B MX 366837B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- multiple myeloma
- quinoline carboxamides
- carboxamides
- quinoline
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185892 | 2014-09-23 | ||
| PCT/EP2015/071391 WO2016042112A1 (en) | 2014-09-23 | 2015-09-18 | Quinoline carboxamides for use in the treatment of multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017003294A MX2017003294A (es) | 2017-06-23 |
| MX366837B true MX366837B (es) | 2019-07-26 |
Family
ID=51660309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003294A MX366837B (es) | 2014-09-23 | 2015-09-18 | Quinolinas carboxamidas para usarse en el tratamiento de mielomas multiples. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9956212B2 (en:Method) |
| EP (1) | EP3041472B1 (en:Method) |
| JP (1) | JP6647287B2 (en:Method) |
| KR (1) | KR102533033B1 (en:Method) |
| CN (1) | CN107108510B (en:Method) |
| AU (1) | AU2015316824B2 (en:Method) |
| CA (1) | CA2961978C (en:Method) |
| EA (1) | EA030948B1 (en:Method) |
| ES (1) | ES2631194T3 (en:Method) |
| IL (1) | IL251043B (en:Method) |
| MX (1) | MX366837B (en:Method) |
| NZ (1) | NZ730816A (en:Method) |
| PL (1) | PL3041472T3 (en:Method) |
| WO (1) | WO2016042112A1 (en:Method) |
| ZA (1) | ZA201702377B (en:Method) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108510B (zh) * | 2014-09-23 | 2020-10-23 | 活跃生物技术有限公司 | 用于治疗多发性骨髓瘤的喹啉甲酰胺 |
| KR20220149579A (ko) * | 2020-03-03 | 2022-11-08 | 액티브 바이오테크 에이비 | 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염 |
| PL4185292T3 (pl) | 2020-07-23 | 2025-10-13 | Erasmus University Medical Center Rotterdam | Białka s100 jako nowe cele terapeutyczne w przypadku nowotworów mieloproliferacyjnych |
| MX2023008016A (es) | 2021-01-18 | 2023-07-13 | Active Biotech Ab | Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico. |
| PL4346773T3 (pl) | 2021-05-25 | 2025-11-03 | Active Biotech Ab | Duża liczba cząstek taskwinimodu i ich zastosowanie |
| JP2024524158A (ja) | 2021-07-02 | 2024-07-05 | アクティブ バイオテック エイビー | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| PL199781B1 (pl) * | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US9469876B2 (en) * | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| EA021171B1 (ru) | 2010-07-09 | 2015-04-30 | Эктив Байотек Аб | Способ получения хинолин-3-карбоксамидов |
| US20140148350A1 (en) * | 2010-08-18 | 2014-05-29 | David Spetzler | Circulating biomarkers for disease |
| WO2012034543A1 (es) | 2010-09-13 | 2012-03-22 | Universidad De Costa Rica | Conector estructural para bambú |
| FR2967353B1 (fr) * | 2010-11-16 | 2013-08-16 | Centre Nat Rech Scient | Derives de quinolinone |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| CN107108510B (zh) * | 2014-09-23 | 2020-10-23 | 活跃生物技术有限公司 | 用于治疗多发性骨髓瘤的喹啉甲酰胺 |
-
2015
- 2015-09-18 CN CN201580051397.XA patent/CN107108510B/zh active Active
- 2015-09-18 AU AU2015316824A patent/AU2015316824B2/en active Active
- 2015-09-18 PL PL15763622T patent/PL3041472T3/pl unknown
- 2015-09-18 EA EA201790687A patent/EA030948B1/ru not_active IP Right Cessation
- 2015-09-18 NZ NZ730816A patent/NZ730816A/en unknown
- 2015-09-18 US US15/510,728 patent/US9956212B2/en active Active
- 2015-09-18 ES ES15763622.6T patent/ES2631194T3/es active Active
- 2015-09-18 JP JP2017513751A patent/JP6647287B2/ja active Active
- 2015-09-18 MX MX2017003294A patent/MX366837B/es active IP Right Grant
- 2015-09-18 KR KR1020177010510A patent/KR102533033B1/ko active Active
- 2015-09-18 CA CA2961978A patent/CA2961978C/en active Active
- 2015-09-18 EP EP15763622.6A patent/EP3041472B1/en active Active
- 2015-09-18 WO PCT/EP2015/071391 patent/WO2016042112A1/en not_active Ceased
-
2017
- 2017-03-09 IL IL251043A patent/IL251043B/en active IP Right Grant
- 2017-04-04 ZA ZA2017/02377A patent/ZA201702377B/en unknown
-
2018
- 2018-04-06 US US15/947,279 patent/US10314836B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2631194T3 (es) | 2017-08-29 |
| US10314836B2 (en) | 2019-06-11 |
| US9956212B2 (en) | 2018-05-01 |
| ZA201702377B (en) | 2018-08-29 |
| JP2017528473A (ja) | 2017-09-28 |
| CA2961978A1 (en) | 2016-03-24 |
| EA030948B1 (ru) | 2018-10-31 |
| AU2015316824B2 (en) | 2020-10-29 |
| AU2015316824A1 (en) | 2017-04-27 |
| CA2961978C (en) | 2023-03-14 |
| CN107108510A (zh) | 2017-08-29 |
| KR102533033B1 (ko) | 2023-05-15 |
| CN107108510B (zh) | 2020-10-23 |
| EA201790687A1 (ru) | 2017-08-31 |
| WO2016042112A1 (en) | 2016-03-24 |
| BR112017004947A2 (pt) | 2017-12-05 |
| PL3041472T3 (pl) | 2017-08-31 |
| NZ730816A (en) | 2022-01-28 |
| KR20170052691A (ko) | 2017-05-12 |
| MX2017003294A (es) | 2017-06-23 |
| JP6647287B2 (ja) | 2020-02-14 |
| IL251043B (en) | 2020-02-27 |
| IL251043A0 (en) | 2017-04-30 |
| US20180228794A1 (en) | 2018-08-16 |
| US20170273967A1 (en) | 2017-09-28 |
| EP3041472B1 (en) | 2017-02-01 |
| EP3041472A1 (en) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| ZA201701299B (en) | Glycosidase inhibitors | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| EP3209653A4 (en) | Process for the preparation of (r,s)-nicotine | |
| GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| TN2015000519A1 (en) | Small molecule inhibitors of fibrosis | |
| PH12015501588A1 (en) | Compounds and methods for treating bacterial infections | |
| AU2015352440B2 (en) | Compounds | |
| TN2016000535A1 (en) | Ppar compounds for use in the treatment of fibrotic diseases. | |
| MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
| MX2015008829A (es) | Momelotinib deuterado. | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| SG11201700039TA (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
| SA517381678B1 (ar) | مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي | |
| NZ732704A (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| PL3119752T3 (pl) | Związki 3,4-diamino-6-chloropirazyno-2-karbokysamidowe do leczenia chorób mediowanych przez ENAC | |
| MX2018002193A (es) | Metodo de uso de quinoxalinilo-piperazinamida. | |
| PH12016502466A1 (en) | Ppar compounds for use in the treatment of fibrotic diseases | |
| TH104715B (th) | สารประกอบและวิธีการสำหรับการรักษาการติดเชื้อแบคทีเรีย | |
| UA91886U (uk) | 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |